Patents by Inventor Motti HAKIM

Motti HAKIM has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF CANCER WITH ANTI-ILT2 ANTIBODIES
    Publication number: 20250019441
    Abstract: The present invention relates to treatment of cancer using an anti-human ILT2 monoclonal antibody. The treatment may additionally comprise pembrolizumab, optionally with chemotherapy, or cetuximab.
    Type: Application
    Filed: July 11, 2024
    Publication date: January 16, 2025
    Applicants: BIOND BIOLOGICS LTD., GENZYME CORPORATION
    Inventors: Dana Haves Ziv, Liat Tevel, Enas Halumi, Nyra Goldstein, Tsuri Peretz, Ilana Goldshtein, Tal Gabay, Anna Fridam-Dror, Itay Friedman, Sharon Hashmueli, Motti Hakim, Ilana Mandel, Avidor Shulman, Yair Sapir, Tehila Ben-Moshe, Giovanni Abbadessa, Meijing Wu, Nigel Patrick Somerville Crawford, Rui Wang, Maria Agarwal, Cecilia Deantonio, Raymond Perez, Ji Lin
  • Methods and compositions for decreasing soluble immune receptor CD28
    Patent number: 12139534
    Abstract: Methods of treating cancer and improving immunotherapies comprising decreasing soluble immune receptor levels are provided. Agents that bind membranal immune receptor and inhibit proteolytic cleavage of the receptor and agents that bind soluble immune receptor and that are neither receptor agonists nor antagonists are also provided, as are methods of producing these agents.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: November 12, 2024
    Assignee: BIOND BIOLOGICS LTD.
    Inventors: Motti Hakim, Dror Alishekevitz, Dana Haves Ziv, Edna Meilin, Yair Sapir, Avidor Shulman, Tehila Ben-Moshe, Ilana Mandel
  • INTRACELLULAR DELIVERY COMPOSITIONS
    Publication number: 20240350648
    Abstract: Protein conjugates comprising a protein carrier comprising a plurality of amine groups, a biological payload that interacts with an intracellular target and a linker linking them, wherein at least a portion of the amine groups are bound to a protecting group are provided. Pharmaceutical compositions comprising the protein conjugates as well as methods of using and producing the protein conjugates are also provided.
    Type: Application
    Filed: May 2, 2024
    Publication date: October 24, 2024
    Inventors: Orit SHILOVITZKY, Lilach CHEN ZELTSBURG, Rozi Ravit UZAN GUETA, Ayala LEWKOWICZ, Yossi GOTTFRIED, Rotem FAYGENBOIM-ORNAI, Bat-Hen EYLON, Shay FREILICH, Motti HAKIM, Yair SAPIR, Ilana MANDEL, Tehila BEN-MOSHE, Avidor SHULMAN
  • METHODS AND COMPOSITIONS FOR DECREASING SOLUBLE IMMUNE RECEPTOR CD28
    Publication number: 20240309094
    Abstract: Methods of treating cancer and improving immunotherapies comprising decreasing soluble immune receptor levels are provided. Agents that bind membranal immune receptor and inhibit proteolytic cleavage of the receptor and agents that bind soluble immune receptor and that are neither receptor agonists nor antagonists are also provided, as are methods of producing these agents.
    Type: Application
    Filed: June 6, 2024
    Publication date: September 19, 2024
    Inventors: Motti HAKIM, Dror ALISHEKEVITZ, Dana HAVES ZIV, Edna MEILIN, Yair SAPIR, Avidor SHULMAN, Tehila BEN-MOSHE, Ilana MANDEL
  • Antibodies against ILT2 and use thereof
    Patent number: 12071479
    Abstract: The present disclosure provides monoclonal anti-ILT2 antibodies or antigen-binding fragments thereof, as well as pharmaceutical compositions comprising the same and methods of producing the same. Also provided are methods of treating cancer using the antibodies or compositions of the present disclosure. Methods of patient selection are also provided.
    Type: Grant
    Filed: August 11, 2021
    Date of Patent: August 27, 2024
    Assignee: BIOND BIOLOGICS LTD.
    Inventors: Ilana Mandel, Tsuri Peretz, Dana Haves Ziv, Ilana Goldshtein, Dror Alishekevitz, Anna Fridman-Dror, Motti Hakim, Avidor Shulman, Yair Sapir, Tehila Ben-Moshe
  • CD28 SHEDDING BLOCKING AGENTS
    Publication number: 20240279335
    Abstract: Single domain antibodies (sdAbs) that block CD28 cleavage are provided. Dimeric agents at least two membranal CD28 binding agents are also provided, as are methods of using the sdAbs and/or dimeric agents and pharmaceutical compositions and kits comprising the sdAbs and/or dimeric agents.
    Type: Application
    Filed: September 6, 2022
    Publication date: August 22, 2024
    Inventors: Anna FRIDMAN-DROR, Tal GABAY, Motti HAKIM, Lilach CHEN ZELTSBURG, Ayala LEWKOWICZ, Ilana MANDEL, Tehila BEN-MOSHE, Yair SAPIR, Avidor SHULMAN
  • INTRACELLULAR DELIVERY COMPOSITIONS
    Publication number: 20240148886
    Abstract: Protein conjugates comprising a protein carrier comprising polyethylenimine, a payload that interacts with an intracellular target and a linker are provided. Pharmaceutical composition comprising the protein conjugates as well as methods of using and producing the protein conjugates are also provided.
    Type: Application
    Filed: October 18, 2023
    Publication date: May 9, 2024
    Inventors: Orit SHILOVITZKY, Lilach CHEN ZELTSBURG, Rozi Ravit UZAN GUETA, Ayala LEWKOWICZ, Yossi GOTTFRIED, Rotem FAYGENBOIM-ORNAI, Motti HAKIM, Yair SAPIR, Ilana MANDEL, Tehila BEN-MOSHE, Avidor SHULMAN
  • IMMUNOMODULATORY COMPOSTIONS AND USE THEREOF
    Publication number: 20240010706
    Abstract: Chimeric molecules comprising a fibrinogen-related domain (FRED) from human fibrinogen-like protein 2 (FGL2) are provided. Immunomodulatory pharmaceutical compositions comprising the chimeric molecules, as well as methods for reducing inflammation and treating autoimmune disease in a subject by administering the chimeric molecules or immunomodulatory pharmaceutical compositions are also provided.
    Type: Application
    Filed: March 31, 2021
    Publication date: January 11, 2024
    Inventors: Ilana MANDEL, Motti HAKIM, Zohar KEREN, Yair SAPIR, Avidor SHULMAN, Tehila BEN-MOSHE
  • SOLUBLE CD28 LEVELS AFTER IMMUNOTHERAPY
    Publication number: 20230221325
    Abstract: Methods of determining suitability of a subject suffering from cancer or at risk of cancer relapse to receive treatment comprising an agent that reduces sCD28 levels are provided. Methods of treating a subject suffering from cancer or at risk of cancer relapse comprising administering an anti-PD-1/PD-L1 immunotherapy, measuring soluble CD28 levels in a subject, and administering an agent that reduces sCD28 levels to a subject whose sCD28 levels increased are also provided.
    Type: Application
    Filed: March 22, 2023
    Publication date: July 13, 2023
    Inventors: Anna FRIDMAN-DROR, Tal GABAY, Orit SHILOVIZKY, Dror ALISHEKEVITZ, Ilana MANDEL, Tehila BEN-MOSHE, Yair SAPIR, Avidor SHULMAN, Motti HAKIM
  • SHEDDING BLOCKING AGENTS WITH INCREASED STABILITY
    Publication number: 20230144459
    Abstract: Agents comprising at least two moieties separated by a linker, wherein a first moiety binds mCD28 on a surface of a cell and inhibits proteolytic cleavage of the mCD28 and wherein a second moiety increases stability of the first moiety are provided. Methods of treating cancer and improving immunotherapy comprising administering the agents are also provided.
    Type: Application
    Filed: March 11, 2021
    Publication date: May 11, 2023
    Inventors: Motti HAKIM, Anna FRIDMAN-DROR, Ilana MANDEL, Tehila BEN-MOSHE, Yair SAPIR, Avidor SHULMAN, Lilach Chen ZELTSBURG, Ayala LEWKOWICZ
  • USE OF MMP INHIBITION
    Publication number: 20230041599
    Abstract: Methods of decreasing shedding of CD28, decreasing soluble CD28 levels, treating cancer and improving immunotherapies comprising inhibiting matrix metalloproteases are provided. Methods of producing agents for performance of the methods of the invention are also provided.
    Type: Application
    Filed: December 2, 2020
    Publication date: February 9, 2023
    Inventors: Motti HAKIM, Anna FRIDMAN-DROR, Ilana MANDEL, Tehila BEN-MOSHE, Yair SAPIR, Avidor SHULMAN
  • SOLUBLE CD28 LEVELS DURING IMMUNOTHERAPY
    Publication number: 20230035730
    Abstract: Methods of diagnosing and predicting cancer relapse comprising measuring soluble CD28 levels in a subject, wherein an increase in soluble CD28 is indicative of cancer relapse or imminent cancer relapse, are provided. Methods of determining response to PD-1/PD-L1 based immunotherapy in a subject in need thereof, comprising measuring sCD28 levels in a subject undergoing PD-1/PD-L1 based immunotherapy at at least two time points wherein a decrease indicates response and an increase indicates lack of response, are also provided.
    Type: Application
    Filed: December 2, 2020
    Publication date: February 2, 2023
    Inventors: Motti HAKIM, Anna FRIDMAN-DROR, Orit SHILOVIZKY, Dror ALISHEKEVITZ, Ilana MANDEL, Tehila BEN-MOSHE, Yair SAPIR, Avidor SHULMAN
  • SMALL SHEDDING BLOCKING AGENTS
    Publication number: 20220169732
    Abstract: Agents that are less than 100 kilodaltons, bind a membranal immune receptor on a surface of a cell and inhibit proteolytic cleavage of the immune receptor are provided. Methods of treating cancer and improving immunotherapy comprising administering the agents are also provided.
    Type: Application
    Filed: March 12, 2020
    Publication date: June 2, 2022
    Inventors: Motti HAKIM, Anna FRIDMAN-DROR, Dror ALISHEKEVITZ, Edna MEILIN, Ilana MANDEL, Tehila BEN-MOSHE, Avidor SHULMAN, Yair SAPIR
  • Antibodies Against ILT2 and Use Thereof
    Publication number: 20220153836
    Abstract: The present invention provides monoclonal antibodies, or antigen-binding portions thereof, against ILT2, as well as pharmaceutical compositions comprising same and methods of producing same. Also provided are methods of treating cancer comprising administering the antibodies or compositions of the invention. Methods of treating cancer, combination treatments, and patient selection are also provided.
    Type: Application
    Filed: November 23, 2021
    Publication date: May 19, 2022
    Applicant: Biond Biologics Ltd.
    Inventors: Ilana MANDEL, Tsuri PERETZ, Dana HAVES ZIV, Ilana GOLDSHTEIN, Dror ALISHEKEVITZ, Anna FRIDMAN-DROR, Motti HAKIM, Avidor SHULMAN, Yair SAPIR, Tehila BEN-MOSHE
  • A METHOD FOR IMMUNOSUPPRESSION
    Publication number: 20220153845
    Abstract: The present invention, in some embodiments thereof, is directed to a method for suppressing an immune response in a subject, including administering to the subject a therapeutically effective amount of an agent having specific binding affinity to a soluble immune receptor.
    Type: Application
    Filed: March 12, 2020
    Publication date: May 19, 2022
    Inventors: Motti HAKIM, Dror ALISHEKEVITZ, Edna MEILIN, Ilana MANDEL, Tehila BEN-MOSHE, Yair SAPIR, Avidor SHULMAN
  • Antibodies Against ILT2 and Use Thereof
    Publication number: 20220048991
    Abstract: The present disclosure provides monoclonal anti-ILT2 antibodies or antigen-binding fragments thereof, as well as pharmaceutical compositions comprising the same and methods of producing the same. Also provided are methods of treating cancer using the antibodies or compositions of the present disclosure. Methods of patient selection are also provided.
    Type: Application
    Filed: August 11, 2021
    Publication date: February 17, 2022
    Applicant: Biond Biologics Ltd.
    Inventors: Ilana MANDEL, Tsuri PERETZ, Dana HAVES ZIV, Ilana GOLDSHTEIN, Dror ALISHEKEVITZ, Anna FRIDMAN-DROR, Motti HAKIM, Avidor SHULMAN, Yair SAPIR, Tehila BEN-MOSHE
  • Antibodies against ILT2
    Patent number: 11236162
    Abstract: The present invention provides monoclonal antibodies, or antigen-binding portions thereof, against ILT2, as well as pharmaceutical compositions comprising same and methods of producing same. Also provided are methods of treating cancer comprising administering the antibodies or compositions of the invention. Methods of treating cancer, combination treatments, and patient selection are also provided.
    Type: Grant
    Filed: April 6, 2021
    Date of Patent: February 1, 2022
    Assignee: Biond Biologies Ltd.
    Inventors: Ilana Mandel, Tsuri Peretz, Dana Haves Ziv, Ilana Goldshtein, Dror Alishekevitz, Anna Fridman-Dror, Motti Hakim, Avidor Shulman, Yair Sapir, Tehila Ben-Moshe
  • Antibodies Against ILT2 and Use Thereof
    Publication number: 20210277112
    Abstract: The present invention provides monoclonal antibodies, or antigen-binding portions thereof, against ILT2, as well as pharmaceutical compositions comprising same and methods of producing same. Also provided are methods of treating cancer comprising administering the antibodies or compositions of the invention. Methods of treating cancer, combination treatments, and patient selection are also provided.
    Type: Application
    Filed: April 6, 2021
    Publication date: September 9, 2021
    Applicant: Biond Biologics Ltd.
    Inventors: Ilana MANDEL, Tsuri PERETZ, Dana HAVES ZIV, Ilana GOLDSHTEIN, Dror ALISHEKEVITZ, Anna FRIDMAN-DROR, Motti HAKIM, Avidor SHULMAN, Yair SAPIR, Tehila BEN-MOSHE
  • METHODS AND COMPOSITIONS FOR DECREASING SOLUBLE IMMUNE RECEPTOR CD28
    Publication number: 20210047411
    Abstract: Methods of treating cancer and improving immunotherapies comprising decreasing soluble immune receptor levels are provided. Agents that bind membranal immune receptor and inhibit proteolytic cleavage of the receptor and agents that bind soluble immune receptor and that are neither receptor agonists nor antagonists are also provided, as are methods of producing these agents.
    Type: Application
    Filed: March 14, 2019
    Publication date: February 18, 2021
    Inventors: Motti HAKIM, Dror ALISHEKEVITZ, Dana HAVES ZIV, Edna MEILIN, Yair SAPIR, Avidor SHULMAN, Tehila BEN-MOSHE, Ilana MANDEL